
1063TiPENGOT-EN9/LEAP-001: A phase III, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer
Marth, C, Vulsteke, C, Rubio, M J, Makker, V, Braicu, E I, McNeish, I A, Radoslaw, M, Ayhan, A, Hasegawa, K, Wu, X, Dutta, L, Xu, C, Keefe, S M, Lee, J, Pignata, SVolume:
30
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdz250.071
Date:
October, 2019
Fichier:
PDF, 78 KB
2019